President Donald Trump’s recent attack on health insurers and the Affordable Care Act subsidies has caused a stir in the stock market. Trump’s criticism of “big, fat, rich insurance companies” receiving ACA subsidies has put companies like UnitedHealth Group (UNH) in the spotlight.
UnitedHealth Group, the parent company of UnitedHealthcare, has seen its stock drop nearly 15% in the last month. This decline comes at a time when the future of ACA subsidies is uncertain, with Marketplace tax credits set to expire soon. Despite these challenges, UNH remains a key player in the managed care marketplace, serving both employer and individual accounts, as well as Medicare and Medicaid accounts through its subsidiary, Optum.
The company has a market capitalization of $280 billion, but its stock has taken a hit, down 48% in the last 12 months. This performance lags behind competitors like Cigna Group and Humana, as well as the broader S&P 500 Index. However, UNH’s fundamentals are solid, with a price-earnings ratio below the industry average and a healthy dividend yield of 2.8%.
Despite recent setbacks, UnitedHealth Group has shown resilience in its third-quarter earnings report. The company reported revenue growth of 12% year-over-year, although earnings were down due to miscalculations on costs related to new Medicare Advantage patients. Additionally, the company faces a Justice Department probe into alleged Medicare fraud, adding to its challenges.
However, there is optimism surrounding UNH stock, with Warren Buffett’s Berkshire Hathaway disclosing a significant stake in the company. UnitedHealth Group is taking steps to address its issues, including planned premium increases and cost-saving measures using artificial intelligence. CEO Stephen Hemsley remains bullish on the company’s outlook, raising full-year guidance and emphasizing a focus on growth.
Analysts have a “Moderate Buy” rating on UNH stock, with a consensus price target that suggests upside potential. While there are risks, including political uncertainty and regulatory challenges, the long-term outlook for UnitedHealth Group appears positive. Despite Trump’s criticisms and the ongoing debate over ACA subsidies, UNH stock presents a buying opportunity for investors looking for exposure to the healthcare sector.
This article was originally published on Barchart.com and does not reflect any personal positions in the mentioned securities. All information and data provided is for informational purposes only.
